Aura Biosciences, Inc. SEC Filings

Aura Biosciences reported Q3 2025 results, highlighting ongoing late-stage development of bel-sar and continued investment in R&D. Net loss was $26.1 million (basic and diluted loss per share $0.40) on total operating expenses of $27.9 million, driven by research and development of $22.2 million and general and administrative of $5.7 million. Other income was $1.8 million.

Liquidity remained solid with $47.6 million in cash and cash equivalents and $114.3 million in marketable securities as of September 30, 2025. Total assets were $190.0 million and stockholders’ equity was $156.7 million. Shares outstanding were 62,985,569 at quarter-end; 63,503,269 as of November 10, 2025.

Year to date, operating cash use was $64.3 million, offset by financing inflows including the May 2025 follow-on that raised approximately $69.9 million net (common shares, pre-funded warrants, and accompanying warrants) and Q3 activity under the ATM. Management expects current cash and marketable securities to fund operations for at least 12 months from issuance. The Phase 3 CoMpass trial in early choroidal melanoma is ongoing, with enrollment targeted for 2026 and a 15‑month primary endpoint readout planned for Q4 2027.

Aura Biosciences announced its financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1. The company also updated its corporate presentation for investor and analyst meetings, filed as Exhibit 99.2. The press release is furnished under Item 2.02, while the presentation is filed under Item 8.01.

The materials include forward-looking statements covering development timelines, regulatory interactions, manufacturing, commercialization plans, market opportunities, and financing needs. The company notes an expected cash runway into the first half of 2027, with outcomes subject to clinical, regulatory, and operational risks described in its risk factor disclosures.

Aura Biosciences (AURA) filed a Form 4 disclosing that its Senior Vice President, Finance sold 896 shares of common stock at $6.35 on 10/29/2025. According to the filing, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and was automatic, not at the reporting person’s discretion.

Following the transaction, the officer directly holds 85,662 shares of Aura Biosciences common stock.

Aura Biosciences (AURA) Form 4: President and Chief Executive Officer (also a Director) reported an automatic sale tied to tax withholding from RSU vesting. On 10/29/2025, the reporting person sold 9,049 shares of common stock at $6.35 per share (Transaction Code S).

Following the transaction, beneficial ownership was 474,391 shares held directly and 127,763 shares held indirectly through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016. The filing notes the sale was executed solely to satisfy tax obligations and not at the reporting person’s discretion.

Aura Biosciences (AURA) reported an insider transaction by its Chief Technology Officer. On 10/16/2025, the officer sold 12,169 shares of common stock at $6.35 per share. Following the sale, the officer directly held 197,287 shares.

The filing states the sale was executed to cover tax withholding obligations upon the vesting of restricted stock units and was automatic, not at the officer’s discretion.

Aura Biosciences insider filing reports option exercises and a partial sale to cover costs. On 08/18/2025 Senior Vice President, Finance Amy Elazzouzi exercised long-held options to purchase 12,899 shares of Aura common stock across multiple option tranches and exercise prices. Of those shares, 7,722 were sold in multiple transactions at prices ranging from $6.57 to $6.80 (weighted average reported as $6.70). Following the transactions the reporting person beneficially owns 86,558 shares and holds no remaining derivative securities from the exercised options. The filing states the specific exercise prices and vesting/exercise dates for each option tranche.

AURA Form 144 notice reports a proposed sale of 7,722 common shares acquired by stock option exercise on 08/18/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $51,750.53 based on the filing. The filing states there were 62,119,873 shares outstanding at the time. No other securities were reported sold in the prior three months and payment for the acquired shares was in cash.

Aura Biosciences, Inc. is the issuer covered by this Schedule 13G/A filed by multiple Frazier Life Sciences entities and individuals. The filing shows that Frazier Life Sciences Public Fund, L.P. directly holds 3,113,550 shares of Aura common stock, reported as 5.0% of the class based on the issuer's reported outstanding share counts used in the filing.

The statement also discloses additional direct holdings across related Frazier vehicles: 918,510 shares by the Public Overage Fund, 128,520 by FLS X, 342,210 by FLS XI and 597,210 by FLS XII. Several prefunded warrants are listed (for example, 778,388 warrants held by FLSPF), each subject to a 9.99% beneficial ownership exercise limit. The filing corrects prior attributions to certain investment-committee members and clarifies which entities directly hold the securities.

Aura Biosciences disclosure: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen report shared beneficial ownership positions in Aura Biosciences common stock. Suvretta and Aaron Cowen each report 4,701,775 shares (7.6% of the class); Averill Master Fund reports 4,137,797 shares (6.6% of the class). Each reporting person states no sole voting or dispositive power and reports shared voting and dispositive power for the stated shares. The filing describes pre-funded warrants exercisable subject to a Maximum Percentage cap of 9.99%, which may be increased to up to 19.99% with written notice effective after 61 days; as a result, not all warrants are presently exercisable and the number of shares issuable upon exercise may change with changes in outstanding common stock. The securities reported are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.